|Bid||12.08 x 1100|
|Ask||18.84 x 1400|
|Day's range||15.72 - 16.94|
|52-week range||8.06 - 23.70|
|Beta (5Y monthly)||0.06|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2023 - 03 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||28.88|
Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
The consensus price target hints at a 95.5% upside potential for Repare Therapeutics Inc. (RPTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.